UbiVac   Report issue

For profit Phase 2
Founded: Portland OR United States (2005)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2013
NCT01909752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 5